Mather Group LLC. Has $1.71 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mather Group LLC. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,770 shares of the medical research company’s stock after selling 404 shares during the quarter. Mather Group LLC.’s holdings in Thermo Fisher Scientific were worth $1,713,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Security National Bank lifted its holdings in shares of Thermo Fisher Scientific by 0.4% in the third quarter. Security National Bank now owns 9,924 shares of the medical research company’s stock worth $6,139,000 after acquiring an additional 38 shares during the last quarter. New England Research & Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 94.3% in the 3rd quarter. New England Research & Management Inc. now owns 2,215 shares of the medical research company’s stock valued at $1,370,000 after acquiring an additional 1,075 shares during the last quarter. Bank of New Hampshire grew its position in Thermo Fisher Scientific by 11.5% during the 3rd quarter. Bank of New Hampshire now owns 1,456 shares of the medical research company’s stock worth $901,000 after acquiring an additional 150 shares during the last quarter. Foster Group Inc. bought a new position in Thermo Fisher Scientific in the third quarter valued at about $208,000. Finally, Salvus Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 3.5% during the third quarter. Salvus Wealth Management LLC now owns 1,132 shares of the medical research company’s stock valued at $700,000 after purchasing an additional 38 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on TMO shares. Robert W. Baird raised their price objective on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Evercore ISI raised their price target on shares of Thermo Fisher Scientific from $605.00 to $630.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. UBS Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Stephens assumed coverage on Thermo Fisher Scientific in a research report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price target on the stock. Finally, Bank of America lifted their price objective on Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $653.72.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $595.14 on Wednesday. The stock has a market cap of $227.34 billion, a P/E ratio of 38.17, a P/E/G ratio of 3.83 and a beta of 0.77. The business’s fifty day moving average is $609.35 and its 200 day moving average is $582.90. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. During the same period in the previous year, the firm posted $5.15 earnings per share. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be issued a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 860 shares of the company’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the completion of the sale, the chief accounting officer now owns 1,814 shares in the company, valued at $1,108,408.42. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the completion of the sale, the chief accounting officer now owns 1,814 shares in the company, valued at approximately $1,108,408.42. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 6,300 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $602.09, for a total value of $3,793,167.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $74,548,375.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,084 shares of company stock worth $14,094,292. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.